Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics' Q2 Loss Rises in Advance of Commercialization Efforts

NEW YORK (GenomeWeb News) - Rosetta Genomics today reported that its second-quarter net loss rose around 61 percent as the firm received approval from the State of New York to offer its first miRNA-based diagnostic test for differentiating squamous from non-squamous non-small cell lung cancer.
The Rehovot, Israel-based company had no revenues for the three-month period ended June 30. It expects to launch the first test later this year through Columbia University Medical Center’s High Complexity Molecular Pathology Laboratory.
Rosetta’s net loss for the second quarter was $3.7 million, or $.31 per share, compared to a net loss of $2.3 million, or $.19 per share, for the second quarter of 2007.
The firm’s R&D costs increased 23 percent to $2.2 million from $1.7 million year over year, and its marketing and business development expenses inched up to $434,000 from $412,000. Its general and administrative costs rose 51 percent to $896,000 from $595,000 for the second quarter of 2007.
Rosetta finished the quarter with $12.1 million in cash and cash equivalents.
Rosetta President and CEO Amir Avniel noted that the firm expects to submit two additional tests — one for differentiating mesothelioma from adenocarcinomas in the lung and one for identifying the primary origin of a metastasis — for regulatory approval in “the coming months.” He also said that the firm would soon begin development of tests at its newly acquired CLIA lab.
Rosetta said last month that it would acquire Parkway Clinical Laboratories, a privately held CLIA-certified lab, for $2.9 million and an additional $300,000 if certain milestones are met.
The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.